‘Dupilumab,’ moderate-to-severe eczema therapy, lands in Korea
‘Dupilumab,’ a moderate-to-severe eczema treatment for adults, will land in the Korean market.
As of 30 March, the Ministry of Food and Drug Safety(MFDS) approved Sanofi-Aventis Korea’s ‘Dupixent Prefilled Inj 300mg(generic name: dupilumab)’ as new drug.
‘Dupilumab’ is a targeted biologic thera...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.